Drug Trial Radar · NCT04262804
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Last checked: Nov 20, 2026Latest source record: Aug 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
123
Actual
Start
Jan 13, 2020
Primary completion
Sep 3, 2021
Study completion Dec 2023
Sponsor
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multi-center, Phase II clinical study to evaluate the efficacy and safety of margetuximab plus chemotherapy compared with trastuzumab plus chemotherapy in Chinese patients (Mainland, Hong Kong and Taiwan) with advanced HER2+ breast cancer who have received at least 2 prior lines of anti-HER2 directed therapy in the metastatic setting (mandatory including trastuzumab). The primary endpoint of this study is PFS evaluated by BICR. The secondary endpoints are OS, PFS evaluated by investigator, ORR, DoR, CBR, safety and tolerability, the impact of ADA, and the popPK profile
Conditions
- Breast Cancer Metastatic
Interventions
MargetuximabDrug
Margetuximab IV
TrastuzumabDrug
Trastuzumab IV
Chosen Chemotherapy (Capecitabine)Drug
Capecitabine tablet
Chosen Chemotherapy (Vinorelbine )Drug
Vinorelbine IV
Chosen Chemotherapy (Gemcitabine )Drug
Gemcitabine IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS assessed by BICR (RECIST 1.1)Time frame: Approximately 18 months after the first subject is randomized; anticipated evaluation Jul 2020.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.